z-logo
open-access-imgOpen Access
Methemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: A case-report
Author(s) -
Desirée Verde Lopes,
Felippe Lazar Neto,
Lais C. Marques,
Rodrigo B.O. Lima,
Antonio Adolfo Guerra Soares Brandão
Publication year - 2020
Publication title -
idcases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.319
H-Index - 13
ISSN - 2214-2509
DOI - 10.1016/j.idcr.2020.e01013
Subject(s) - medicine , methemoglobinemia , hemolytic anemia , hemolysis , anemia , hemoglobin , respiratory distress , gastroenterology , immunology , anesthesia
We report a second case of methemoglobinemia and non-autoimmune hemolytic anemia after contracting the SARS-CoV-2 infection in the absence of an identifiable eliciting drug. A 35-year old male without previous known comorbidities was admitted after he was diagnosed with the COVID-19 infection and had large pulmonary involvement. Seven days later, he desaturated but was without any signs of respiratory distress. A check of arterial blood gas revealed normal partial pressure of oxygen and follow-up tests confirmed a methemoglobinemia diagnosis. Over the next few days, hemolysis was established after decreased levels of hemoglobin and increased levels of indirect bilirubin and lactate dehydrogenase. A hemolytic anemia investigation panel came back normal, including G6PD. A second G6PD test was ordered at the 5-month follow-up appointment and revealed decreased levels. Clinicians should thus be aware of possible false negative tests when testing for G6PD during hemolytic crisis. In addition, whether the COVID-19 infection alone would be responsible for this chain of events remains a challenging question.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom